Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel)
work together in treating patients with Richter's syndrome. Richter's syndrome occurs
when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an
aggres...
Age: 18 years - 66+
Gender: All
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood
cell responsible for fighting infections). The purpose of this study is to assess the
safety and tolerability of epcoritamab in combination with anti-neoplastic agents in
adult p...
Age: 18 years - 66+
Gender: All
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma
A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety,
tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of
epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NH...
Age: 18 years - 66+
Gender: All
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this trial is to measure the safety and effectiveness of epcoritamab
(EPKINLY™), either by itself or together with other therapies, when treating subjects
with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to
identify t...
Age: 18 years - 66+
Gender: All